Portal de Periódicos da CAPES

Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism

1992; Elsevier BV; Volume: 102; Issue: 4 Linguagem: Inglês

10.1378/chest.102.4_supplement.364s

1931-3543

Mark Levine, Samuel Z. Goldhaber, Robert M. Califf, Joel M. Gore, Jack Hirsh,

Acute Ischemic Stroke Management

Bleeding is the major side effect of thrombolytic therapy. It usually occurs at a site of vascular invasion but can be spontaneous. Intracranial bleeding is the most feared bleeding complication occurring in between 0.3 and 1 percent of patients treated with streptokinase (SK), anisoylated plasminogen streptokinase activator complex (anistreplase or APSAC) or recombinant tissue plasminogen activator (rtPA) for myocardial infarction. Bleeding is an inevitable consequence of effects of plasmin-mediated proteolysis.